Research graph
References from <scp>COVID</scp> ‐19‐associated intractable mucormycosis successfully treated with nivolumab and interferon‐gamma. Local targets link to admitted publications; unresolved targets remain external evidence.
A systematic review on SARS‐CoV‐2‐associated fungal coinfections
10.1002/jmv.27358 · 2022 · External reference
Multicenter epidemiologic study of coronavirus disease‐associated mucormycosis, India
10.3201/eid2709.210934 · 2021 · External reference
T‐cells of invasive candidiasis patients show patterns of T‐cell‐exhaustion suggesting checkpoint blockade as treatment option
10.1016/j.jinf.2021.12.009 · 2021 · External reference
Nivolumab plus interferon‐gamma in the treatment of intractable mucormycosis
10.1016/s1473-3099(16)30541-2 · 2017 · External reference
Immune checkpoint blockade for aspergillosis and mucormycosis coinfection
2021 · External reference
Interferon‐gamma immunotherapy in a patient with refractory disseminated candidiasis
10.1097/inf.0000000000000909 · 2015 · External reference
